newsfilter
← Latest News
Business Wire·

Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021

Lenzilumab significantly improved the likelihood of survival without ventilation (SWOV) by 54% versus standard treatment in hospitalized patients with COVID-19 pneumonia IDWeek is the premier global scientific meeting that brings together infectio